JP2017508741A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508741A5
JP2017508741A5 JP2016554498A JP2016554498A JP2017508741A5 JP 2017508741 A5 JP2017508741 A5 JP 2017508741A5 JP 2016554498 A JP2016554498 A JP 2016554498A JP 2016554498 A JP2016554498 A JP 2016554498A JP 2017508741 A5 JP2017508741 A5 JP 2017508741A5
Authority
JP
Japan
Prior art keywords
gglu
desb27
eps
human insulin
desb30 human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554498A
Other languages
English (en)
Japanese (ja)
Other versions
JP6580583B2 (ja
JP2017508741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053989 external-priority patent/WO2015128403A2/en
Publication of JP2017508741A publication Critical patent/JP2017508741A/ja
Publication of JP2017508741A5 publication Critical patent/JP2017508741A5/ja
Application granted granted Critical
Publication of JP6580583B2 publication Critical patent/JP6580583B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554498A 2014-02-28 2015-02-26 リシン22のイプシロン位においてアシル化された、A22K、desB27、B29R、desB30ヒトインスリン類似体 Active JP6580583B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14157215 2014-02-28
EP14157215.6 2014-02-28
PCT/EP2015/053989 WO2015128403A2 (en) 2014-02-28 2015-02-26 Novel insulin derivatives and the medical uses hereof

Publications (3)

Publication Number Publication Date
JP2017508741A JP2017508741A (ja) 2017-03-30
JP2017508741A5 true JP2017508741A5 (enExample) 2018-04-05
JP6580583B2 JP6580583B2 (ja) 2019-09-25

Family

ID=50184804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554498A Active JP6580583B2 (ja) 2014-02-28 2015-02-26 リシン22のイプシロン位においてアシル化された、A22K、desB27、B29R、desB30ヒトインスリン類似体

Country Status (23)

Country Link
US (1) US10040839B2 (enExample)
EP (1) EP3110840B1 (enExample)
JP (1) JP6580583B2 (enExample)
KR (1) KR20160125988A (enExample)
CN (1) CN106459171B (enExample)
AR (1) AR099569A1 (enExample)
AU (1) AU2015222135B2 (enExample)
BR (1) BR112016017193A2 (enExample)
CA (1) CA2941103A1 (enExample)
DK (1) DK3110840T3 (enExample)
ES (1) ES2831848T3 (enExample)
HR (1) HRP20201732T1 (enExample)
HU (1) HUE051355T2 (enExample)
IL (1) IL246757B (enExample)
MX (1) MX368387B (enExample)
PL (1) PL3110840T3 (enExample)
PT (1) PT3110840T (enExample)
RS (1) RS61137B1 (enExample)
RU (1) RU2684456C2 (enExample)
SA (1) SA516371705B1 (enExample)
SI (1) SI3110840T1 (enExample)
TW (1) TWI686403B (enExample)
WO (1) WO2015128403A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015131902A1 (en) * 2014-03-07 2015-09-11 Jørgensen Klavs Holger Novel fast acting insulin preparations
CN108026157B (zh) 2015-08-25 2022-11-25 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
WO2018094388A1 (en) * 2016-11-21 2018-05-24 Case Western Reserve University Rapid-acting insulin analogues of enhanced stability
KR101909052B1 (ko) * 2017-02-09 2018-10-17 강원대학교산학협력단 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물
EP3606560A2 (en) * 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AU2018317810A1 (en) * 2017-08-17 2020-03-19 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
MA50414A (fr) * 2017-10-19 2020-08-26 Mona E Buice Composition à usage topique pour la cicatrisation améliorée des plaies ouvertes
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
SG11202106168VA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
CA3127312A1 (en) 2019-02-13 2020-08-20 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin derivative having cysteine residue
JP7479302B2 (ja) * 2019-02-13 2024-05-08 住友ファーマ株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
MX2022002433A (es) * 2019-08-27 2022-05-19 Zp Spv 3 K/S Análogos de compstatina y sus usos médicos.
MA58093B1 (fr) 2019-12-11 2024-09-30 Novo Nordisk A/S Nouveaux analogues d'insuline et leurs utilisations
WO2021136293A1 (zh) * 2019-12-30 2021-07-08 甘李药业股份有限公司 胰岛素衍生物
JP2024521757A (ja) * 2021-05-24 2024-06-04 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 新規なアシル化インスリンアナログ

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ ノルディスク アクティーゼルスカブ ヒトインシュリン類似物質
EP0506792B1 (en) * 1989-12-21 1995-05-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
BR9407508A (pt) 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AU720966B2 (en) 1995-03-17 2000-06-22 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
ATE321783T1 (de) 1997-03-20 2006-04-15 Novo Nordisk As Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden.
AU757933B2 (en) 1997-10-24 2003-03-13 Novo Nordisk A/S Aggregates of human insulin derivatives
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
EA200000453A1 (ru) 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
WO1999034821A1 (en) 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
EP1086130A1 (en) 1998-06-12 2001-03-28 Kings College London Insulin analogue
EP1196446A1 (en) 1999-06-29 2002-04-17 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
AU2001264789A1 (en) 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003048195A2 (en) 2001-12-02 2003-06-12 Novo Nordisk A/S Glucose dependant release of insulin from glucose sensing insulin derivatives
BR0215029A (pt) 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
WO2003075950A1 (en) 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
US20060183667A1 (en) 2003-07-11 2006-08-17 Novo Nordisk A/S Stabilised insulin compositions
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
AU2004264958B2 (en) 2003-08-13 2010-04-15 Biocon, Ltd Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ ノルディスク アクティーゼルスカブ アシル化されたインスリンの製造方法
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
RU2527893C2 (ru) 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
ES2490243T3 (es) 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー/エス インスリン組成物および組成物の製造方法
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー/エス 新規インシュリン誘導体
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
EP2076242B8 (en) 2006-07-27 2013-02-20 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー/エス ペグ化持続型インスリン
US9018161B2 (en) * 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
WO2009015456A1 (en) 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
JP5715418B2 (ja) 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー/エス インスリン誘導体
ES2430042T3 (es) 2007-11-16 2013-11-18 Novo Nordisk A/S Composiciones farmacéuticas estables que comprenden liraglutida y degludec
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
ES2618073T3 (es) * 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
WO2010029159A1 (en) 2008-09-12 2010-03-18 Novo Nordisk A/S Method of acylating a peptide or protein
EP2352513B1 (en) 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
CA2744558A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2448962B1 (en) 2009-06-30 2016-10-19 Novo Nordisk A/S Insulin derivatives
CA2769540C (en) * 2009-07-31 2017-08-15 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
WO2011141407A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
JP5973427B2 (ja) 2010-06-23 2016-08-23 ノヴォ ノルディスク アー/エス 追加のジスルフィド結合を含有するインスリン類似体
WO2011161125A1 (en) * 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
US9655974B2 (en) 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
AU2012328407A1 (en) 2011-10-27 2014-05-22 Case Western Reserve University Ultra-concentrated rapid-acting insulin analogue formulations

Similar Documents

Publication Publication Date Title
JP2017508741A5 (enExample)
RU2016135543A (ru) Новые производные инсулина и их применение в медицине
RU2012128547A (ru) Дважды ацилированные производные glp-1
CY1125006T1 (el) Λιπαρα οξεα και η χρηση τους σε συνδυασμο με βιομορια
RU2013148921A (ru) Дважды ацилированные производные glp-1
JP2013543853A5 (enExample)
JP2018506507A5 (enExample)
RU2015132860A (ru) Композиции инсулинов длительного действия
RU2018107727A (ru) Новые производные инсулина и их медицинские применения
JP2013533227A5 (enExample)
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
JP2014529629A5 (enExample)
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
JP2014503526A5 (enExample)
CN114901682A (zh) 胰岛素衍生物
AR082995A1 (es) Profarmacos que comprenden un conjugado de conector de exendina
JP2019526537A5 (enExample)
RU2013131913A (ru) Твердые композиции, содержащие агонист glp и соль n-(2-гидроксибензоил)амино)каприловой кислоты
WO2009044392A3 (en) Novel sirna structures
MY189770A (en) Biaryl derivative as gpr120 agonists
UA114700C2 (uk) Тверда фармацевтична форма для перорального застосування та процес її виготовлення
JP2017514801A5 (enExample)
RU2012150108A (ru) Аналоги глюкагоноподобного пептида-1 и их применение
JP2018505859A5 (enExample)
JP2013530974A5 (enExample)